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Purpose/Objective: The Esteya® electronic brachytherapy 
system (Elekta Brachytherapy, The Netherlands) has been 
recently developed for HDR brachytherapy treatment of skin 
lesions, using a 69.5 kVp X-ray source. The purpose of this 
study was to evaluate the surface dose rate of the Esteya by 
using different detectors and calibration protocols. Results 
are compared considering the uncertainty of each method. 
Materials and Methods: The surface dose rates of the 15, 20, 
25 and 30 mm diameter applicators of Esteya were measured 
with the plane parallel ionization chamber T34013 (PTW-
Freiburg, Germany) and the parallel plate ionization chamber 
Exradin A20 (Standard Imaging Inc., USA). The first one was 
calibrated in both air and water, whereas the second one was 
provided with calibration in air. Measurements in air were 
performed according to dosimetric protocol established by 
the Task Group 61 of the American Association of Physicists in 
Medicine, whereas measurements in water were performed in 
a CIRS Plastic Water® phantom, using the methodology 
proposed by the International Atomic Energy Agency in its 
report TRS-398. Measurements were corrected by the 
effective point of measurement in each case. 
Results: Table 1 shows the relative differences between the 
experimental measurements of this study and the internal 
values used by Esteya to determine the treatment times. The 
relative uncertainty (with coverage factor k = 1) of the 
absorbed dose measurements are: 2.5% for the T34013 
chamber calibrated in water, 2.7% for the T34013 chamber 
calibrated in air, and 2.6% for the A20 chamber calibrated in 
air. Relative differences between the output factors 
measured in air with the ionization chamber T34013 and the 
A20 are below 2%, which are lower than the uncertainties of 
the dose measurements, so the stem effect of the PTW 
chamber can be considered to be negligible for this 
application. 
Conclusions: The two ionization chambers and the two 
dosimetric protocols have been shown to provide consistent 
results with the internal values from Esteya, considering the 
uncertainties. Further investigation is needed to evaluate the 
equivalence between plastic water and liquid water. Because 
measurements in air require more correction factors and 
because the experimental setup used with solid plastic is 
more similar to the real patient setup, measurements with a 
chamber calibrated in water seem to provide a more direct 
methodology to characterize dosimetrically the Esteya 
system.  
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Purpose/Objective: To test the hypothesis that radiotherapy 
(RT) of head and neck squamous cell carcinoma (HNSCC) can 
be improved by hypoxic modification using nimorazole (NIM) 
in association with accelerated fractionation. 
Materials and Methods: The IAEA-HypoX protocol was 
activated March 2012 as an international multicentre 
randomized trial in patients with HNSCC. The tumour was 
treated to a dose of 66-70 Gy, 33-35 fractions, 6 fractions per 
week. NIM was administered as a total dose of 1.2 g per m2 
body surface area, 90 minutes before the first daily RT 
fraction. The primary endpoint was loco-regional failure. The 
analysis was perfor-med as intention to treat among 
evaluable patients. The trial was closed prematurely by June 
2014 due to insufficient recruitment. This was caused by 
inability to obtain the approval for using the drug in three 
major centres and an insufficient recruitment rate in the 
active participating centres. An associated quality assurance 
program was performed to insure the consistency with the 
protocol guidelines. 
Results: The trial was dimensioned to include 600 patients in 
3 years, but between March 2012 and May 2014 only 104 
patients were randomized. All 20 patients from two centres 
had to be excluded from the final analysis due to the 
unavailability of the follow-up data. Thus, only four of nine 
centres originally planned to participate did contribute to the 
study.  
Among the 84 eligible patients, 2 patients did not start RT 
after randomization. The remaining 82 patients were 
evaluable (39 and 43 patients in the RT+NIM and the RT-alone 
arms, respectively). The treatment compliance was good 
with only six patients not completing the full planned 
radiotherapy course, and with 32 patients (82%) out of 39 
allocated for nimorazole, achieved at least 75% of the 
prescribed drug dose. The cause of failure to fulfil the 
treatment was mainly due to the acute side effects.  
At the time of evaluation, 36 patients had failed to achieve 
persistent loco-regional control, and a total of 40 patients 
